F. M. Sirotnak - Concepedia

Author

F. M. Sirotnak

Memorial Sloan Kettering Cancer Center

Also Known As

F M Sirotnak, F Sirotnak, F. M. SIROTNAK, F. M. Sirotnak, F. Sirotnak, F.M. Sirotnak, Frances M Sirotnak, S C Grant

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University University of Maryland, College Park Phoenixville Hospital

About

F. M. Sirotnak is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	712
2	Natural Sciences	7	7	394
3	Education	1	1	15
4	Health Sciences	1	1	41
5	Public Health	1	1	15

F. M. Sirotnak

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. F. M. Sirotnak, D. M. Moccio, L. E. Kelleher, PubMed Kinetic PropertiesMixed-phenotype Acute LeukemiaResistant PhenotypesRelative FrequencyRedox Biology	1981	189
Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression Eunice S. Wang, Owen A. O’Connor, Yuhong She, Leukemia & lymphoma/Leukemia and lymphoma	2003	113
New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Franz A. Schmid, F. M. Sirotnak, Glenys M. Otter, PubMed ImmunologyPharmacotherapyHuman Tumor XenograftsTumor BiologyMedicinal Chemistry	1985	69
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Yuhong She, Fei Lee, Jing Chen, PubMed	2003	68
Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors. F. M. Sirotnak, Ruth C. Donsbach PubMed Hematological MalignancyTumor BiologyKinetic CorrelatesTherapeutic ResponsivenessMedicine	1976	64
Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events F. M. Sirotnak, Yuhong She, Nushmia Z. Khokhar, Molecular Carcinogenesis	2004	48
Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux. F. M. Sirotnak, D. M. Moccio, Charles W. Young PubMed Metronomic ChemotherapySteady State LevelCellular PhysiologyPharmacokineticsTumor Biology	1981	47
Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin Joseph I. DeGraw, Vernon H. Brown, H. Tagawa, Journal of Medicinal Chemistry	1982	47
Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Adam P. Dicker, Mark Waltham, Matthias Volkenandt, Proceedings of the National Academy of Sciences Mixed-phenotype Acute LeukemiaPathologyTumor BiologyDrug ResistanceHematological Malignancy	1993	41
Amino Acid Metabolism of Bovine Rumen Bacteria F. M. Sirotnak, R. N. Doetsch, Richard E. Brown, Journal of Dairy Science	1953	37

Page 1